Indian pharma company Glenmark Pharmaceuticals has introduced the antiviral drug Favipirvir Fabiflu tablet for patients with mild and moderate symptoms of Covid-19.
FaviFavipirvir Fabiflu tablet
Pharmaceutical company Glenmark Pharmaceuticals has received permission to test favipirvir tablets on corona virus-infected patients. The company claimed on Thursday that it was the first company in the country to get such approval from the Drug Controller General of India (DCGI).
The company said that it is the first company in the country to get regulatory permission for drug testing on corona virus patients. Favipiravir is an anti-viral drug. This drug has shown the correct response against influenza virus.
The use of this Favipirvir medicine for the treatment of the influenza virus is permitted in Japan. As per the rules, the company will test it on select 150 patients partially infected with Coronavirus and the duration of the test on the patient cannot exceed 14 days. The company said that ‘Favipiravir will be one tablet of 200mg and the maximum price for the leaf of 34 tablets will be Rs 3,500.
The company says that two doses of 1800 mg will have to be taken on the first day. After that, two doses of 800 mg will have to be taken for 14 days. The company has also said that people suffering from diabetes or heart disease will also be able to take this medicine. Apart from this, DCGI has also instructed that it should be used only on young people, while in addition to liver and kidney patients, pregnant and lactating women should not be given this medicine.
According the news Glenmark would work closely with the government and the medical community to quickly reach Fabiflu for patients around the country. It provides rapid reduction of viral load within four days and rapid symptomatic and radiological improvement.
Medical experts said that how effective this drug will be known in the coming months.
For more information about this drug please visit the official company website